Loyola University

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Acute lymphoblastic leukaemia1 trial
• Atrial fibrillation1 trial
• Coronary artery disease1 trial
• Idiopathic pulmonary fibrosis1 trial
• Lewy body dementia1 trial
• Multiple system atrophy1 trial
• Osteoporosis1 trial
• Parkinson disease1 trial
• Vascular dementia1 trial

Phase

• Phase 1/21 trial
• Phase 21 trial
• Phase 41 trial

Status

• Completed4 trials
• Not yet recruiting1 trial
• Recruiting1 trial

Lead sponsor

• California Pacific Medical Center Research Institute1 trial
• Kite, A Gilead Company1 trial
• Shockwave Medical, Inc.1 trial
• University of Alabama at Birmingham1 trial
• University of Chicago1 trial
• and 1 more

Running trials

• Not yet recruiting

  Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis

  NCT07674745· Phase 2· University of Alabama at Birmingham· Source

  Contact: Dan Dilling, MD

• Recruiting

  Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study

  NCT05677880· University of Wisconsin, Madison· Source

  Contact: Cadasil Consortium

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Idiopathic pulmonary fibrosis1 recruiting
• Vascular dementia1 recruiting

Closed trials

• Completed

  Shockwave C2+ 2Hz Coronary IVL Catheter in Calcified Coronary Arteries (Disrupt CAD DUO)

  NCT05966662· Shockwave Medical, Inc.· Source

• Completed

  Studying Heart Ablation After Left Atrial Closure in High-Bleeding-Risk Atrial Fibrillation Patients

  NCT07580937· University of Chicago· Source

• Completed

  Trial of Parkinson's And Zoledronic Acid

  NCT03924414· Phase 4· California Pacific Medical Center Research Institute· Source

• Completed

  A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

  NCT02614066· Phase 1/2· Kite, A Gilead Company· Source